Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMHN Wayrilz (rilzabrutinib) Coverage Update | Open…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.751

    Rilzabrutinib (Wayrilz) — Coverage Criteria for Immune Thrombocytopenia

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.751 alerts

    Get alerted when Policy CP.PHAR.751 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for rilzabrutinib (Wayrilz) for adults with persistent or chronic immune thrombocytopenia (ITP) across commercial, HIM, and Medicaid lines of business.

    Policy Summary
    Payermhn
    PolicyRilzabrutinib (Wayrilz) — Coverage Criteria for Immune Thrombocytopenia
    Policy CodePolicy CP.PHAR.751
    Change TypeFormulary redirectionoperational update
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionObtain prior authorization with documentation demonstrating diagnosis of persistent or chronic ITP, hematologist involvement, age ≥18, qualifying platelet count or active bleed, prior corticosteroid and eltrombopag failure (unless contraindicated), and dosing within limits.
    SourceLink
    POLICY UPDATE CHANGES

    Added redirection to generic Promacta for ITP and removed redirection to immune globulin if intolerant or contraindicated to systemic corticosteroid.

    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration
    800 mg/dayMax daily dose
    400 mg BIDTypical dosing
    ≥18Eligible age
    Platelets <30k/µLLab criterion

    Coverage Criteria for Wayrilz (rilzabrutinib)

    Initial Therapy

    Covered when ALL of the following are met

    Initial Approval - ITP: Diagnosis of persistent or chronic immune thrombocytopenia (ITP); prescribed by or in consultation with a hematologist; age ≥ 18 years; one of the following: (a) current (within 30 days) platelet count < 30,000/µL, or (b) member has an active bleed; failure of a systemic corticosteroid unless contraindicated or clinically significant adverse effects; failure of eltrombopag (Promacta) unless contraindicated or clinically significant adverse effects; Wayrilz is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist (e.g., Doptelet, Promacta, Mulpleta, Nplate), or a spleen tyrosine kinase inhibitor (e.g., Tavalisse); dose does not exceed 800 mg (2 tablets) per day.N/A

    Approval duration: 12 months

    Continuation Therapy

    Covered when ALL of the following are met

    Continued Therapy - ITP: Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria, or (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; member is responding positively to therapy (e.g., increase in platelet count from baseline, reduction in bleeding events); Wayrilz is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist (e.g., Doptelet, Promacta, Mulpleta, Nplate), or a spleen tyrosine kinase inhibitor (e.g., Tavalisse); if request is for a dose increase, new dose does not exceed 800 mg (2 tablets) per day.N/A

    Approval duration: 12 months

    Coverage does not extend to non‑FDA approved indications that are not specifically addressed by this policy. For any off‑label use, the provider must supply sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid), or other applicable evidence of coverage documents.

    Use of the medication for indications that are not FDA‑approved and not addressed in this policy is not authorized unless the submission includes adequate documentation meeting the referenced off‑label use policy standards. Requests lacking such documentation will be considered non‑covered.

    Initial Approval Criteria

    Initial Therapy

    Initial approval requirements for ITP

    Initial use: Diagnosis of persistent or chronic ITP; prescribed by or in consultation with a hematologist; age ≥18 years; platelet <30,000/µL within 30 days or active bleed; failure of systemic corticosteroid unless contraindicated; failure of eltrombopag unless contraindicated; Wayrilz not used concurrently with rituximab, a thrombopoietin receptor agonist, or a spleen tyrosine kinase inhibitor; dose ≤ 800 mg/day (typical regimen 400 mg PO BID).N/A

    Approval duration: 12 months

    Criteria for Continued Coverage

    Continued Therapy

    Criteria for continued coverage

    Continued use: Member is currently receiving medication via the benefit or previously met initial approval criteria (or is in continuity of care); member is responding to therapy (e.g., increase in platelet count from baseline or reduction in bleeding events as defined by response criteria); Wayrilz is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist, or a spleen tyrosine kinase inhibitor; if dose increase requested, new dose does not exceed 800 mg/day.N/A

    Approval duration: 12 months

    Coding and Product Information

    Product availability / NDCNDC
    NDCTablet: 400 mg
    inv-06: Platelet count threshold — < 30,000/µL
    Platelet threshold for initiationCurrent platelet count < 30,000/µL (within 30 days) is a qualifying laboratory criterion for initial approval.
    Response definition (ASH 2019)Response defined as platelet count ≥ 30,000/µL and >2-fold increase from baseline on two occasions >7 days apart without bleeding.
    Failure definition (ASH 2019)Failure defined as platelet count < 30,000/µL or <2-fold increase from baseline or presence of bleeding; platelet counts measured on ≥2 occasions >1 day apart.

    Prior Authorization, Documentation, and Denials

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must include documentation demonstrating that the member meets criteria for treatment of persistent or chronic immune thrombocytopenia (ITP) and other policy requirements.

    • Affected drug: Wayrilz (rilzabrutinib)
    • Approval duration: 12 months
    • Maximum dose: 800 mg (2 tablets) per day
    Step Therapy

    Step Therapy Requirements

    Step therapy requires documented failure of specified prior therapies before approval of Wayrilz, unless contraindicated or clinically significant adverse effects are documented.

    • Required failures: systemic corticosteroid and eltrombopag (Promacta) prior to Wayrilz
    • Document contraindications or clinically significant adverse effects if exceptions are claimed

    Step Therapy Requirements

    StepRequirementNotes
    1Prior failure of a systemic corticosteroid is required unless contraindicated or clinically significant adverse effects are experienced.Per Initial Approval Criteria: failure of systemic corticosteroid (see Appendix B).
    2Prior failure of eltrombopag (generic Promacta) is required unless contraindicated or clinically significant adverse effects are experienced.Policy added redirection to generic Promacta for ITP (see references).
    3Step therapy requirement does not apply to Illinois HIM requests effective 1/1/2026 per IL HB 5395.Illinois HIM exemption noted in policy footnote.
    4Wayrilz must not be prescribed concurrently with rituximab, a thrombopoietin receptor agonist, or a spleen tyrosine kinase inhibitor.Concurrent use prohibition is part of initial approval conditions; dose must also not exceed 800 mg/day.

    Quantity Limits and Dispensing

    inv-17: Wayrilz (rilzabrutinib) — 2 tablets
    Quantity limit2 tablets per day (400 mg tablet; maximum 800 mg/day).
    Typical dosing regimen400 mg PO twice daily (400 mg tablet).
    Maximum daily dose800 mg/day (equivalent to 2 tablets).

    Site-of-Care Restrictions

    Note

    No site‑of‑care restrictions

    No site‑of‑care restrictions are specified in this policy.

    Clinical Definitions and Response Criteria

    inv-12: ITP timing definitions
    Newly diagnosed ITPDiagnosis to 3 months.
    Persistent ITP3 to 12 months from diagnosis.
    Chronic ITPGreater than 12 months from diagnosis.
    inv-13: Treatment response/failure
    Treatment response (2019 ASH)Platelet count ≥ 30,000/µL and >2-fold increase from baseline on two occasions >7 days apart without bleeding.
    Treatment failure (2019 ASH)Platelet count < 30,000/µL, or <2-fold increase from baseline, or presence of bleeding; platelet counts should be measured on ≥2 occasions more than 1 day apart.

    Background

    This policy specifically lists diagnoses and indications for which coverage is not authorized. Non‑FDA approved indications not addressed in this policy require demonstration of efficacy and safety per the applicable off‑label policies before coverage will be considered.

    Revision History & Policy Changes

    2025-12-04formulary_redirection

    Added redirection to generic Promacta for ITP and removed redirection to immune globulin if intolerant or contraindicated to systemic corticosteroid.

    2025-09-09policy_creation

    Policy created (initial document creation).

    2025-11-25p_and_t_approval

    Policy received P&T approval.

    Policy Summary
    Payermhn
    PolicyRilzabrutinib (Wayrilz) — Coverage Criteria for Immune Thrombocytopenia
    Policy CodePolicy CP.PHAR.751
    Change TypeFormulary redirectionoperational update
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionObtain prior authorization with documentation demonstrating diagnosis of persistent or chronic ITP, hematologist involvement, age ≥18, qualifying platelet count or active bleed, prior corticosteroid and eltrombopag failure (unless contraindicated), and dosing within limits.
    SourceLink
    On This Page
    Coverage Criteria for Wayrilz (rilzabrutinib)Initial Approval CriteriaCriteria for Continued CoverageCoding and Product InformationPrior Authorization, Documentation, and DenialsStep Therapy RequirementsQuantity Limits and DispensingSite-of-Care RestrictionsClinical Definitions and Response CriteriaBackgroundRevision History & Policy Changes
  1. For IL HIM members (from 2026-01-01), step therapy does not apply per IL HB 5395
  2. Documentation Required

    Required Documentation

    Provider must submit supporting clinical documentation with the prior authorization request to demonstrate that all approval criteria are met.

    • Diagnosis documentation: evidence of persistent or chronic ITP (see Appendix D)
    • Lab results: current platelet count (within 30 days) or documentation of active bleeding
    • Therapy history: documentation of trial and failure/intolerance of systemic corticosteroid and eltrombopag, or documented contraindication/adverse effects
    • Specialist involvement: note indicating prescribed by or in consultation with a hematologist
    • For continuation: evidence of clinical response (increase in platelet count from baseline or reduced bleeding events) or prior approval records
    Denial Risk

    Reasons for Denial

    Requests may be denied if the member does not meet policy criteria or required documentation is missing or inadequate.

    • Insufficient documentation of diagnosis (persistent/chronic ITP) or absence of required lab results
    • Member under 18 years of age
    • No documentation of failure of systemic corticosteroid and/or eltrombopag and no documented contraindication
    • Concurrent prescription with rituximab, TPO receptor agonist (Promacta/Doptelet/Mulpleta/Nplate), or spleen tyrosine kinase inhibitor (Tavalisse)
    • Requested dose exceeds 800 mg (2 tablets) per day
    Measurement timing for response
    Two occasions >7 days apart for response assessment.
    2025-02-26p_and_t_approvalLatest

    P&T approval recorded for formulary changes noted in December SDC.